A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Trial Profile

A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2016 Planned number of patients changed from 182 to 200.
    • 28 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top